%PDF-1.3
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2019-02-11T16:13:49+01:00
2019-02-11T16:13:51+01:00
2019-02-11T16:13:51+01:00
Adobe InDesign CC 14.0 (Macintosh)
uuid:3efd4247-f8ef-2840-ab70-de04cab914d4
xmp.did:FC2A661B33206811822AA6C89601A394
xmp.id:37e518d9-40ad-4bd7-887f-886eb4e3344a
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 14.0 (Macintosh)
/
2019-02-11T16:13:49+01:00
xmp.iid:ffecf658-c323-4d07-afd9-534e132723a7
xmp.did:FC2A661B33206811822AA6C89601A394
xmp.did:FC2A661B33206811822AA6C89601A394
default
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
8 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 24706>>/PageWidthList<0 595.276>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>>
endobj
6 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 38573>>/PageWidthList<0 595.276>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>>
endobj
7 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 38574>>/PageWidthList<0 595.276>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>>
endobj
10 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 38611>>/PageWidthList<0 595.276>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>>
endobj
34 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
12 0 0 12 56.6929 25.8225 Tm
(188)Tj
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
8 0 0 8 56.6929 794.0024 Tm
[(Nutr)12 (afoods \(2018\) 17:185-188)]TJ
ET
q
0 g
/GS1 gs
0 TL/Fm1 Do
Q
0.75 0.05 1 0 K
0.5 w
/GS1 gs
q 1 0 0 1 56.6929 97.8051 cm
0 0 m
231.024 0 l
S
Q
BT
/GS0 gs
0.09 Tw 9 0 0 9 56.6929 760.8898 Tm
[(tients as ev)24 (aluated b)18 (y the attending ph)37 (ysicians. It w)18 (as also )]TJ
0.267 Tw 0 -1.667 Td
(reported that spontaneous osteogenesis started earlier in )Tj
-0.033 Tw 0 -1.667 Td
[(complicated )0.5 (fr)12 (actures )0.6 (w)17.9 (hen )0.6 (BCP )0.5 (w)18 (as )0.5 (administered. )0.5 (One )0.6 (pa)]TJ
0 Tw (-)Tj
0.034 Tw 0 -1.667 Td
(tient in the BCP group experienced an extremely shortened )Tj
-0.045 Tw 0 -1.667 Td
[(healing )0.5 (process, )0.5 (w)17.9 (hic)18 (h )0.5 (w)18 (as )0.5 (reduced )0.5 (from the )0.5 (usual )0.5 (6 )0.5 (to only )]TJ
0 Tw 0 -1.667 Td
(4 weeks.)Tj
0.75 0.05 1 0 k
/GS1 gs
/TT1 1 Tf
12 0 0 12 56.6929 655.8898 Tm
(Discussion)Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0.078 Tw 9 0 0 9 56.6929 625.8898 Tm
[(T)45 (he results of this observ)24 (ational trial demonstr)12 (ated positi)18 (v)12 (e )]TJ
0 Tw 0 -1.667 Td
[(effects on bone healing after the or)12 (al application of BCP)129 (.)]TJ
0.01 Tw 0 -1.667 Td
(In the placebo group, 50% of the patients had a suboptimal )Tj
0.123 Tw 0 -1.667 Td
[(or bad outcome, w)18 (hereas only 21% of the patients in the )]TJ
-0.043 Tw 0 -1.667 Td
[(v)12 (erum group sho)12 (wed a suboptimal or bad result. In the treat)]TJ
0 Tw (-)Tj
0 -1.667 Td
[(ment group, 79% had a v)12 (ery good or a good outcome.)]TJ
-0.001 Tw 0 -1.667 Td
(Elderly patients in particular seem to experience major ben)Tj
0 Tw (-)Tj
/C2_0 1 Tf
0 -1.667 Td
[<004C00C4005B005A0003>0.9 <004D0059005600540003>0.8 <005B004F004C0003>0.9 <00560059>12 <004800530003>0.8 <00500055005B00480052004C0003>0.9 <0056004D0003>0.8 <0029002A0037>129 <00150003>0.9 <002C005D>12 <004C00550003>0.8 <004A00560054005700530050004A0048005B004C004B0003>0.9 <004D0059>12 <0048004A005B005C0059004C005A0003>]TJ
/TT0 1 Tf
0.027 Tw 0 -1.667 Td
[(sho)12 (wed earlier osteogenesis after BCP w)18 (as administered, ir)]TJ
0 Tw 25.336 0 Td
(-)Tj
-25.336 -1.667 Td
[(respecti)18 (v)12 (e of the patient\222)92 (s age.)]TJ
0.175 Tw 0 -1.667 Td
[(T)45 (he pronounced impact of BCP on connecti)18 (v)12 (e tissue has )]TJ
0.113 Tw 0 -1.667 Td
[(been demonstr)12 (ated in sev)12 (er)12 (al clinical studies. )74.4 (T)45 (he positi)18 (v)12 (e )]TJ
0.145 Tw 0 -1.667 Td
(effects on healing of BCP treatment are probably attribut)Tj
0 Tw (-)Tj
-0.051 Tw 0 -1.667 Td
(able to increased bone metabolism due to a direct impact on )Tj
0.034 Tw 0 -1.667 Td
[(extr)12 (acellular matrix turno)12 (v)12 (er)74 (, as well as an additional effect )]TJ
0.016 Tw 0 -1.667 Td
[(on bone miner)12.1 (alization [10, 11]. Shortened healing periods )]TJ
0.066 Tw 0 -1.667 Td
[(with impro)12 (v)12 (ed angiogenesis ha)30 (v)12 (e been observ)12 (ed in animal )]TJ
0.145 Tw 0 -1.667 Td
(experiments [12, 13]. Other studies on humans also con)Tj
0 Tw (-)Tj
/C2_0 1 Tf
0 -1.667 Td
[<00C400590054004C004B0003005A005B00500054005C00530048005B0050005600550003>-0.6 <0056004D0003004E0059>12 <00480055005C00530048005B0050005600550003005B0050005A005A005C004C0003>-0.6 <00480055004B0003005700590056005B004C0048005A004C005A00130003>-0.6 <00480003004B004C>]TJ
/TT0 1 Tf
(-)Tj
/C2_0 1 Tf
0 -1.667 Td
[<004A0059004C0048005A004C0003>41.1 <005000550003>41.1 <0050005500C50048005400540048005B0050005600550003>41.2 <005700480059>12 <00480054004C005B004C0059005A00130003>41.1 <00480055004B0003>41.1 <00500054005700590056>12 <005D>12 <004C004B0003>41.1 <0057004C0059004D005C005A00500056005500130003>]TJ
/TT0 1 Tf
-0.023 Tw 0 -1.667 Td
[(especially with regard to microcir)12 (culation, after BCP admin)]TJ
0 Tw (-)Tj
/C2_0 1 Tf
0 -1.667 Td
[<0050005A005B0059>12 <0048005B0050005600550003>47.3 <00420018001B00130003>47.4 <0018001C004400150003>121.3 <003B>45 <004F004C005A004C0003>47.4 <00C40055004B00500055004E005A0003>47.3 <00540050004E004F005B0003>47.3 <004C005F005700530048005000550003>47.4 <005B004F004C0003>47.3 <0049004C0055004C00C4004A0050004800530003>]TJ
/TT0 1 Tf
0 -1.667 Td
[(results on bone healing observ)12 (ed after BCP treatment.)]TJ
0.75 0.05 1 0 k
/GS1 gs
/TT1 1 Tf
12 0 0 12 56.6929 265.8898 Tm
(Conclusion)Tj
0 0 0 1 k
/GS0 gs
/C2_0 1 Tf
9 0 0 9 56.6929 235.8898 Tm
[<003000550003>-65.2 <005A005C00540054004800590060>92 <00130003>-65.2 <005B004F004C005A004C0003>-65.3 <00C40055004B00500055004E005A0003>-65.2 <005A004F0056>12 <005E0003>-65.2 <004D005600590003>-65.3 <005B004F004C0003>-65.2 <00C40059005A005B0003>-65.2 <005B00500054004C0003>-65.3 <005B004F0048005B0003>-65.2 <0029002A00370003>]TJ
/TT0 1 Tf
-0.01 Tw 0 -1.667 Td
[(ha)30 (v)12 (e a positi)18 (v)12 (e impact on bone healing. )73.5 (T)45 (he data suggest an )]TJ
0.031 Tw 0 -1.667 Td
[(impro)12 (v)12 (ed clinical outcome independent of the type of fr)12 (ac)]TJ
0 Tw (-)Tj
-0.019 Tw 0 -1.667 Td
[(ture. It must, ho)12 (wev)12 (er)74 (, be noted that these results apply only )]TJ
0.07 Tw 0 -1.667 Td
[(for the product used in this stud)24 (y)92 (, as other collagen h)37 (ydro)]TJ
0 Tw (-)Tj
0.053 Tw 0 -1.667 Td
[(lysates or collagen peptides ma)30 (y sho)12 (w different effects. Fu)]TJ
0 Tw (-)Tj
0 -1.667 Td
[(ture studies on a larger population should corrobor)12 (ate these )]TJ
-0.004 Tw 0 -1.667 Td
[(positi)18 (v)12 (e results and attempt to elucidate the mode of action.)]TJ
0.75 0.05 1 0 k
/GS1 gs
/TT1 1 Tf
0 Tw 10 0 0 10 231.0468 100.8898 Tm
(REFERENCES )Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0.037 Tw 7.5 0 0 7.5 56.6929 85.8898 Tm
(1. )Tj
/Span<>> BDC
1.112 0 Td
( )Tj
EMC
0.778 0 Td
[(W)37 (atanabe-Kamiy)24 (ama M, Shimizu M, Kamiy)23.9 (ama S, )74.2 (T)100 (aguc)18 (hi )92.2 (Y)129 (, Sone )]TJ
-0.027 Tw 0 -2 Td
[(H, Morimatsu F)110.9 (, Shir)12 (aka)18 (w)18 (a H, Furuka)18 (w)18 (a )92.3 (Y)129 (, K)37 (omai M \(2010\) )37.2 (Absorp)]TJ
0 Tw (-)Tj
0.043 Tw 33.449 92 Td
[(tion and effecti)18 (v)12 (eness of or)12 (ally administered lo)11.9 (w molecular weight )]TJ
0 Tw 0 -2 Td
[(collagen h)37 (ydrolysate in r)12 (ats. J )37 (Agric F)45 (ood Chem 58:835\226841)]TJ
0.02 Tw -1.89 -2 Td
(2. )Tj
/Span<>> BDC
1.112 0 Td
( )Tj
EMC
0.778 0 Td
[(K\366nig )0.5 (D)45 (, )0.5 (Oesser )0.5 (S, )0.5 (Sc)18 (harla )0.5 (S, )0.5 (Zdzieblik )0.5 (D)45 (, )0.5 (Gollhofer )37.5 (A )0.5 (\(2018\) )0.6 (Spe)]TJ
0 Tw (-)Tj
/C2_0 1 Tf
0 -2 Td
[<004A005000C4004A0003>-221.4 <004A0056005300530048004E004C00550003>-221.5 <0057004C0057005B0050004B004C005A0003>-221.4 <00500054005700590056>12 <005D>12 <004C0003>-221.4 <004900560055004C0003>-221.4 <005400500055004C0059>12 <004800530003>-221.4 <004B004C0055005A0050005B00600003>-221.5 <00480055004B0003>-221.4 <004900560055004C0003>]TJ
/TT0 1 Tf
0.284 Tw 0 -2 Td
[(markers )0.5 (in )0.5 (postmenopausal )0.5 (w)12 (omen )0.5 (\226 )0.5 (a )0.5 (r)12 (andomized )0.5 (controlled )]TJ
0 Tw 0 -2 Td
[(stud)24 (y)92 (. Nutrients 10\(1\). doi:10.3390/nu10010097)]TJ
0.092 Tw -1.89 -2 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Daneault )37 (A, Pr)12 (a)18 (witt J, F)55 (abien Soul\351 )91.9 (V)129 (, Coxam )92 (V)129 (, )36.9 (W)18 (ittr)12 (ant )92 (Y \(2017\) )]TJ
0.076 Tw 0 -2 Td
[(Biological effect of h)37 (ydrolyzed collagen on bone metabolism. Crit )]TJ
0 Tw 0 -2 Td
[(Rev F)45 (ood Sci Nutr 57\(9\):1922\2261937)]TJ
0.099 Tw -1.89 -2 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Shigemur)12 (a )92.3 (Y)129 (, K)30 (ubomur)12 (a D)45 (, Sato )92.2 (Y)129 (, Sato K \(2014\) Dose-dependent )]TJ
0.102 Tw 0 -2 Td
[(c)18 (hanges in the lev)12 (els of free and peptide forms of h)36.9 (ydroxyproline )]TJ
0.061 Tw 0 -2 Td
[(in human )0.5 (plasma )0.5 (after collagen )0.5 (h)37 (ydrolysate ingestion. )0.5 (F)45 (ood Chem )]TJ
0 Tw 0 -2 Td
(159:328\226332)Tj
0.044 Tw -1.89 -2 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Osa)18 (w)18 (a )91.8 (Y)129 (, Mizushige )73.8 (T)111 (, Jinno S, Sugihar)12 (a F)111 (, Inoue N, )73.8 (T)99.9 (anaka H, Ka)]TJ
0 Tw (-)Tj
-0.019 Tw 0 -2 Td
[(buy)24 (ama )92.4 (Y )0.5 (\(2018\) )37.4 (Absorption and metabolism of )0.5 (or)12 (ally administered )]TJ
-0.025 Tw 0 -2 Td
[(collagen )0.5 (h)36.9 (ydrolysates ev)24 (aluated )0.5 (b)17.9 (y )0.5 (the )0.5 (v)23.9 (ascularly perfused )0.5 (r)12 (at intes)]TJ
0 Tw (-)Tj
0 -2 Td
[(tine and li)18 (v)12 (er in situ. Biomed Res \(T)99.9 (ok)18 (y)18 (o\) 39\(1\):1\22611)]TJ
0.026 Tw -1.89 -2 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
(Amizuka N \(2004\) Bone quality in the respect of bone matrix. Clin )Tj
0 Tw 0 -2 Td
(Calcium 14:589\226593)Tj
0.108 Tw -1.89 -2 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Kniep R \(2002\) Knoc)18 (henarbeit mit kristallen und molek\374len. Max )]TJ
0 Tw 0 -2 Td
[(Planc)18 (k F)45 (orsc)18 (hung 04:39\22642)]TJ
-0.042 Tw -1.89 -2 Td
(8.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Adam M, Spacek P)128.9 (, Hulejo)12 (v)24 (a H \(2002\) )37.3 (What is the effect of collagen )]TJ
0.23 Tw 0 -2 Td
[(peptides )0.5 (peror)12 (al )0.5 (administr)12 (ation )0.5 (in )0.5 (postmenopausal )0.5 (osteoporosis? )]TJ
0 Tw 0 -2 Td
(Ces Reumatol 10:131\226137)Tj
0.026 Tw -1.89 -2 Td
(9.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Adam )0.5 (M, )0.5 (Spacek )0.6 (P)128.9 (, )0.6 (Hulejo)12 (v)23.9 (a )0.6 (H, )0.6 (Galiano)12 (v)24 (a )37.4 (A, )0.5 (Blahos )0.5 (J )0.5 (\(1998\) )0.5 (Ma)30 (y )]TJ
0.053 Tw 0 -2 Td
[(Collagen Hydrolysate Ric)17.9 (h Diet \(CHRD\) extend the effect of calci)]TJ
0 Tw (-)Tj
0 -2 Td
[(tonin in postmenopausal osteoporosis? Connect )74 (T)74 (iss Dis 17:25\22636)]TJ
0.14 Tw -1.89 -2 Td
(10.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Br)12 (adley EW)92 (, Oursler MJ \(2008\) Osteoclast culture and resorption )]TJ
0 Tw 0 -2 Td
[(assa)30 (ys. Methods Mol Biol 455:19\22635)]TJ
0.093 Tw -1.89 -2 Td
(11.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Nojiri H, Saita )92 (Y)129 (, Morika)18 (w)18 (a D)44.9 (, K)37 (oba)30 (y)24 (ashi K, )73.9 (Tsuda C, Miy)24 (azaki )73.9 (T)111 (, )]TJ
0.017 Tw 0 -2 Td
[(Saito M, Marumo K, )91.7 (Y)129 (oneza)18 (w)18 (a I, Kaneko K, Shir)12 (asa)18 (w)17.9 (a )73.7 (T)111 (, Shimizu )73.7 (T )]TJ
0.027 Tw 0 -2 Td
[(\(2011\) Cytoplasmic superoxide causes bone fr)12 (agility o)12 (wing to lo)11.9 (w-)]TJ
0.101 Tw 0 -2 Td
[(turno)12 (v)12 (er osteoporosis and impaired collagen cross-linking. J Bone )]TJ
0 Tw 0 -2 Td
(Miner Res 26:2682\2262694)Tj
-0.014 Tw -1.89 -2 Td
(12.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Dang QF)111 (, Liu H, )92.1 (Y)129 (an JQ)24 (, Liu CS, Liu )92.1 (Y)129 (, Li J )]TJ
/TT2 1 Tf
(et al)Tj
/TT0 1 Tf
[( \(2015\) Char)12 (acteriza)]TJ
0 Tw (-)Tj
-0.035 Tw 0 -2 Td
[(tion of collagen from haddoc)18 (k skin and w)12 (ound healing properties of )]TJ
0 Tw 0 -2 Td
[(its h)37 (ydrolysates. Biomed Mater 10\(1\):015022)]TJ
/C2_0 1 Tf
-0.007 Tc 0.007 Tw -1.89 -2 Td
[<0018>-7 <001A>-7 <0015>]TJ
/Span<>> BDC
1.39 0 Td
<0003>Tj
EMC
0.5 0 Td
[<0041004F00480055004E0003>43.2 <004100130003>43.3 <0041004F004800560003>43.2 <003400130003>80.3 <003E>36.9 <00480055004E0003>43.3 <003100130003>43.2 <002B00500055004E0003>135.3 <0040>129 <00130003>43.2 <002B004800500003>43.3 <003F00130003>43.3 <003300500003>135.2 <00400003>43.3 <000F001900170018001800100003>43.2 <00360059>12 <004800530003>43.3 <0048004B0054005000550050005A005B0059>12 <0048>]TJ
/TT0 1 Tf
0 Tc 0 Tw (-)Tj
-0.007 Tc 0.001 Tw 0 -2 Td
[(tion )0.5 (of )0.5 (skin )0.5 (gelatin )0.5 (isolated )0.5 (from )0.5 (Chum )0.5 (salmon )0.5 (\()]TJ
/TT2 1 Tf
[(Oncorh)37 (ync)18 (hus )0.5 (keta)]TJ
/TT0 1 Tf
0 Tc 0 Tw (\) )Tj
-0.007 Tc 0 -2 Td
[(enhances w)12 (ound healing in diabetic r)12 (ats. Mar Drugs 9\(5\):696\226711)]TJ
0 Tc -0.014 Tw -1.89 -2 Td
(14.)Tj
/Span<>> BDC
( )Tj
EMC
1.89 0 Td
[(Nonaka I, Katsuda S, Ohmon )73.8 (T )]TJ
/TT2 1 Tf
(et al)Tj
/TT0 1 Tf
[( \(1997\) In vitro and in vi)18 (v)18 (o anti-)]TJ
0.013 Tw 0 -2 Td
[(platelet effects of enzymatic h)37 (ydrolysates of collagen and collagen-)]TJ
0 Tw 0 -2 Td
[(related peptides. Biosci Biotec)17.9 (hnol Bioc)17.9 (hem 61:772\226775)]TJ
-0.007 Tc 0.106 Tw -1.89 -2 Td
[(1)-7 (5)-7 (.)]TJ
/Span<>> BDC
1.39 0 Td
( )Tj
EMC
0.5 0 Td
[(K)37 (ouguc)18 (hi )74.4 (T)111 (, )0.5 (Ohmon )74.4 (T)111 (, Shimizu M, )74.5 (T)99.9 (akahata )92.5 (Y)129 (, Maey)24 (ama )92.5 (Y)129 (, Suzuki)-7 ( )]TJ
0.016 Tw 0 -2 Td
[(T)111 (, Morimatsu F)110.9 (, )74.4 (T)99.9 (anabe S \(2013\) Effects of a c)17.9 (hic)18 (ken collagen h)36.9 (ydro)]TJ
0 Tc 0 Tw (-)Tj
-0.007 Tc -0.029 Tw 0 -2 Td
[(lysate on the cir)12 (culation system in subjects with mild h)37 (ypertension or)-7 ( )]TJ
-0.039 Tw 0 -2 Td
[(high-normal blood pressure. Biosci Biotec)18 (hnol Bioc)18 (hem 77:691\226696)]TJ
ET
endstream
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 464.9347 25.8134 Tm
[(www)74 (.ceceditore.com)]TJ
ET
0.75 0.05 1 0 K
2 w 4 M 0 j 0 J
/GS1 gs
q 1 0 0 1 56.6929 804.8898 cm
0 0 m
481.89 0 l
S
Q
endstream
endobj
24 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0.375 0.025 0.5 0 k
/GS0 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 475.6998 793.8962 Tm
(ORIGINAL RESEARCH)Tj
ET
0.75 0.05 1 0 K
2 w 4 M 0 j 0 J
q 1 0 0 1 56.6929 37 cm
0 0 m
481.89 0 l
S
Q
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
39 0 obj
<>stream
HdN#G=ObusK\`f2̂OJ>nw7hSާN/}z|:N˷~,_Wf;grus3]~~1/_OWuriߧt{;~~xy>ί?|>c?>^i>7`/a_v۫xf/Nڟ9!ol<4<2:6#ofofofofollFyK*[Uvd^9r$Gy